Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS0159 in NASH
NCT05591079Phase 2Completed
- Sponsor
- Cascade Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of linafexor in Nonalcoholic steatohepatitis (NASH), sponsored by Cascade Pharmaceuticals. Started Feb 2023; status: completed.
02
Drugs
linafexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05591079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05591079.